ConductScience.org, home

Paper30684591

CRISPR-Cas9 for cancer therapy: Opportunities and challenges.

Chen M and 5 others. Cancer Lett, 2019. Cited by 218 papers, by iCite.

Cite this record

ConductScience Library. CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Papers, record 30684591. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30684591

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
PubMed
Journal
Cancer Lett
PubMed
Year
2019
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
Citations, by iCite
218
iCite
Relative citation ratio, by iCite
7.92
iCite
Revised in PubMed
2019-12-17
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen MMinjiang
2Mao AAiwu
3Xu MMin
4Weng QQiaoyou
5Mao JJianting
6Ji JJiansong

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CRISPR-Cas SystemsMajor topic
Clustered Regularly Interspaced Short Palindromic RepeatsMajor topic
NeoplasmsMajor topic
Animals
Gene Editing
Genetic Therapy
Humans

Source PubMed

Download CSV of topics

Cited by147

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 218 citations.

PMIDTitleJournalYearIn PapersSource
42909932Recent advances in CRISPR technologies for biomedical applications and disease treatment.Theranostics2026https://conductscience.org/library/papers/42909932PubMed
42864491The global patent landscape of CRISPR-Cas applications in medicine.Nat Biotechnol2026https://conductscience.org/library/papers/42864491PubMed
42852014Reassessing Viral Gene Therapy for Glioblastoma: Translational Opportunities and Challenges.Yale J Biol Med2026https://conductscience.org/library/papers/42852014PubMed
42799027Bioengineered T-cell therapies for precision immunotherapy in renal transplantation, autoimmune relapse, and sensitization.Clin Kidney J2025https://conductscience.org/library/papers/42799027PubMed
42749951From scissors to editors: how the evolution of precision is redefining therapeutic genome editing.Mol Genet Genomics2026https://conductscience.org/library/papers/42749951PubMed
42698535Impact of oxidative stress on malignant tumor progression and emerging therapeutic strategies.Front Mol Biosci2026https://conductscience.org/library/papers/42698535PubMed
42681653KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomark Res2026https://conductscience.org/library/papers/42681653PubMed
42642601Dissecting Epigenetic Drug Response Mechanisms Using CRISPR Knockout Screens.Methods Mol Biol2026https://conductscience.org/library/papers/42642601PubMed
42610144AI-driven CRISPR strategies in breast cancer: Organoid modeling, adaptive editing, and precision delivery.Iran J Basic Med Sci2026https://conductscience.org/library/papers/42610144PubMed
42509343TRIM27-Cas9-loaded EVs suppress HCC proliferation and enhance responsiveness to anti-PD-1 therapy by promoting ACSL4-mediated ferroptosis.Cell Death Differ2026https://conductscience.org/library/papers/42509343PubMed
42467361CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.MedScience2026https://conductscience.org/library/papers/42467361PubMed
42298891Inducible CRISPR/Cas systems in precision oncology: Current applications and future perspectives.Clin Transl Med2026https://conductscience.org/library/papers/42298891PubMed
42107518Modalities of vision restoration in optic neuropathies and retinal disease.Prog Retin Eye Res2026https://conductscience.org/library/papers/42107518PubMed
42096026Overcoming T cell exhaustion and senescence in CAR T cell therapy for solid tumors.Clin Transl Oncol2026https://conductscience.org/library/papers/42096026PubMed
41999294A novel rapid detection approach based on CRISPR-Cas13a for Dermatophagoides pteronyssinus and Dermatophagoides farinae (Acariformes: Pyroglyphidae).J Insect Sci2026https://conductscience.org/library/papers/41999294PubMed
41984395Nanotechnology advances for psoriasis treatment and future prospects.Discov Nano2026https://conductscience.org/library/papers/41984395PubMed
41930150Next-Generation Hydrogel Platforms for Effective Localized Cancer Therapy: Advances in Biologics, Immunotherapeutics, and Gene Delivery.Oncol Res2026https://conductscience.org/library/papers/41930150PubMed
41893914Current and emerging molecular diagnostic approaches in the detection of human parasites.Parasitol Res2026https://conductscience.org/library/papers/41893914PubMed
41876645Synergistic integration of CRISPR/Cas and nanozymes in next-generation biosensors for ultrasensitive bacterial detection.Mikrochim Acta2026https://conductscience.org/library/papers/41876645PubMed
41755409CRISPR-Cas9 Gene Editing: Promising Therapeutics for HPV-driven Cervical Cancer.Curr Drug Targets2026https://conductscience.org/library/papers/41755409PubMed

See all 147 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30684591

GET https://conductscience.org/api/papers/v1/30684591/cited_by?page=2